Clinical Trial: Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelera
Brief Summary: Maintain and monitor long-term hematological and cytogenetic responses previously obtained by patients participating in the [CAMN107A2109] study
Detailed Summary:
Sponsor: Novartis Pharmaceuticals
Current Primary Outcome: Disease response (complete hematologic response, cytogenetic response) and progression at or until 24 months, depending of the case every 3 months [ Time Frame: 3 - 24 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Novartis
Dates:
Date Received: November 5, 2008
Date Started: August 2008
Date Completion:
Last Updated: February 21, 2017
Last Verified: February 2017